Committees’ opinions on applications for authorisation available

2020-10-07

The consolidated opinions of the Committees for Risk Assessment and Socio-economic Analysis are now available for:

use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (EC -; CAS -) by Lonza Biologics Porriño, SL. and Lonza Biologics, plc.;

two uses (use 1, use 2) of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (EC -; CAS -) by Wallac Oy;

use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (EC -; CAS -) by Rentschler Biopharma SE;

use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (EC -; CAS -) by Teva Baltics UAB; and

use of 4-nonylphenol, branched and linear, ethoxylated (EC -; CAS -) by Sekisui S-lec BV Roermond.

Opinions

ECHA, 7 October 2020
; https://echa.europa.eu/-/echa-weekly-7-october-2020